EGFR and non-small cell lung carcinoma: Results are intriguing considering a study conducted by Cheng et al. [48], which showed that among patients with EGFR-mutated NSCLC, Black patients had shorter survival compared to Non-Black patients (p = 0.001), with 2-year survival rates of 33% vs. 61%, respectively.